Evidence map›Paper›PMID 36723483›Full record

ArticleJournal of proteome research2023

SUMO Proteomics Analyses Identify Protein Inhibitor of Activated STAT-Mediated Regulatory Networks Involved in Cell Cycle and Cell Proliferation.

Chongyang Li, Alison Boutet, Cristina Mirela Pascariu, Trent Nelson, Mathieu Courcelles, Zhaoguan Wu, Simon Comtois-Marotte, Gregory Emery, Pierre Thibault

Open access · hybridAbstract read
In one paragraph

Article in Journal of proteome research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. A Landscape Analysis of Human SUMOylation.Molecular & cellular proteomics : MCP · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Function and regulation of ubiquitin-like SUMO system in heart.Frontiers in cell and developmental biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Chongyang LiInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3T 1J4, Canada.ORCID 0000-0001-6842-4406
Alison BoutetInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3T 1J4, Canada.
Cristina Mirela PascariuInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3T 1J4, Canada.
Trent NelsonInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3T 1J4, Canada.
Mathieu CourcellesInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3T 1J4, Canada.ORCID 0000-0001-5961-8858
Zhaoguan WuInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3T 1J4, Canada.
Simon Comtois-MarotteInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3T 1J4, Canada.
Gregory EmeryInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3T 1J4, Canada.
Pierre ThibaultInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3T 1J4, Canada.ORCID 0000-0001-5993-0331
Institute for Research in Immunology and Cancer · CA

Funding

CIHR PJT - 175093
6 · The paper itself

Abstract

Protein inhibitor of activated STAT (PIAS) proteins are E3 SUMO ligases playing important roles in protein stability and signaling transduction pathways. PIAS proteins are overexpressed in the triple-negative breast cancer cell line MDA-MB-231, and PIAS knockout (KO) results in a reduction in cell proliferation and cell arrest in the S phase. However, the molecular mechanisms underlying PIAS functions in cell proliferation and cell cycle remain largely unknown. Here, we used quantitative SUMO proteomics to explore the regulatory role of PIAS SUMO E3 ligases upon CRISPR/Cas9 KO of individual PIAS. A total of 1422 sites were identified, and around 10% of SUMO sites were regulated following KO of one or more PIAS genes. We identified protein substrates that were either specific to individual PIAS ligase or regulated by several PIAS ligases. Ki-67 and TOP2A, which are involved in cell proliferation and epithelial-to-mesenchymal transition, are SUMOylated at several lysine residues by all PIAS ligases, suggesting a level of redundancy between these proteins. Confocal microscopy and biochemical experiments revealed that SUMOylation regulated TOP2A protein stability, while this modification is involved in the recruitment of Ki-67 nucleolar proteins containing the SUMO interacting motif. These results provide novel insights into both the redundant and specific regulatory mechanisms of cell proliferation and cell cycle mediated by PIAS SUMO E3 ligases.

Indexed as

ProteomicsUbiquitin-Protein LigasesCell CycleCell ProliferationKi-67 AntigenSmall Ubiquitin-Related Modifier ProteinsSumoylationKi-67 AntigenSmall Ubiquitin-Related Modifier ProteinsUbiquitin-Protein Ligasescell proliferationE3 SUMO ligasesKi-67protein inhibitor of activated STAT (PIAS)protein modificationquantitative proteomicsSUMOylationtopoisomerase 2A

Identifiers

PMID36723483
PMCPMC9990128
OpenAlexW4318754879

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.